About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Insights - Eli Lilly's experimental obesity drug demonstrated significant efficacy, with patients losing up to 20.1% of their weight in a mid-stage trial [1] Company Summary - The drug's performance in clinical trials indicates a strong potential for market success, addressing a growing demand for effective obesity treatments [1] Industry Summary - The obesity treatment market is expanding, and successful trials like Eli Lilly's could lead to increased competition and innovation within the sector [1]

Core Insights - Terns Pharmaceuticals has decided to halt the development of its experimental obesity drug due to modest weight loss results and safety concerns raised during a mid-stage trial [1] Company Summary - The decision to stop the drug development was influenced by the trial outcomes, which indicated only modest weight loss [1] - Safety concerns were a significant factor in the decision-making process, suggesting potential risks associated with the drug [1] Industry Summary - The halt in development reflects ongoing challenges in the obesity drug market, where efficacy and safety are critical for success [1] - This incident may impact investor confidence in similar obesity treatments under development by other companies in the industry [1]

Core Insights - Skye Bioscience's experimental obesity drug failed to meet the primary endpoint in a mid-stage clinical trial [1] Company Summary - The company announced the results of its mid-stage study on Monday, indicating that the obesity drug did not achieve its main goal [1]